Research Synthesis: EGCG green tea longevity — full paper

Researka accepted publication: 894c8a6d-e240-4cf7-9da0-061b9f6a2380 Source submission: 9ae401b0-b7a9-4bed-a6f5-76aec3eb781a Evidence-honesty note: 64/78 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 74/78 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Epigallocatechin gallate (EGCG), the dominant catechin in green tea, has attracted substantial interest as a candidate geroprotector, with proposed mechanisms spanning mitochondrial complex I inhibition, anti-inflammatory signaling, and bone-metabolic effects, yet the human evidence base remains fragmented across preclinical, mechanistic, and trial designs. We conducted an AI-assisted structured evidence synthesis with full audit trail, screening 78 curated references across direct human RCTs, mechanistic/preclinical studies, and indirect observational evidence, and resolving each into a canonical outcome class to prevent cross-domain fusion.